NCYT.L

Novacyt S.A.
Novacyt S.A. - Result of AGM
18th July 2024, 15:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 9954W
Novacyt S.A.
18 July 2024
 

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

Result of AGM

 

Paris, France, and Eastleigh and Manchester, UK - 18 July 2024 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that all resolutions proposed at the ordinary general meeting part of the Company's Annual General Meeting (AGM), held today, were duly passed.

 

As part of the AGM, the Company also met today to hold an extraordinary general meeting. The meeting was not deemed quorate due to the minimum number of voting rights under French company law not being present or represented at the meeting. Consequently, the meeting did not take place.

 

Following the AGM, Steve Gibson and Joanne Mason have now formally joined the Novacyt Board, as Executive Directors.

 

The results of the AGM voting will be made available on the Company's website.

 

Contacts

 

Novacyt SA

https://novacyt.com/investors

Lyn Rees, Chief Executive Officer

 Via Walbrook PR

Steve Gibson, Chief Financial Officer 

 


SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

+44 (0)20 3470 0470

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)




Deutsche Numis (Joint Broker)

+44 (0)20 7260 1000

Freddie Barnfield / Duncan Monteith / Michael Palser




Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

 +33 (1) 42 22 10 10
 r.durgetto@allegrafinance.com / y.petit@allegrafinance.com



Walbrook PR (Financial PR & IR)

Stephanie Cuthbert / Paul McManus /

Phillip Marriage / Alice Woodings

+44 (0)20 7933 8780 or novacyt@walbrookpr.com

+44 (0)7796 794 663 / +44 (0)7980 541 893

 +44 (0)7867 984 082 / +44 (0)7407 804 654

 

About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

 

The Company is divided into three business segments:

 

Clinical

Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:

·    Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests

·    Precision Medicine: DPYD genotyping assay

·    Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

Instrumentation

Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:

·    Ranger® Technology: automated DNA sample preparation and target enrichment technology

·    MyGo: real-time quantitative PCR (qPCR) instruments

 

Research Use Only 

Range of services for the life sciences industry:

·    Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry

·    Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

 

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGZVLFFZDLXBBE]]>
TwitterFacebookLinkedIn